Wednesday, October 23, 2019

Bristol-Myers Squibb Loses $6 Billion in Value on Celgene Deal Setback: Brainstorm Health

Author

Categories

Share

Happy Monday, readers!
Bristol-Myers Squibb hasn’t exactly had a pristine path to its proposed acquisition of Celgene. Sure, the legacy pharma giant racked up more than 75% of shareholder votes to approve the $74 billion acquisition following a quickly-quash…
Read More

Author

Share

error: Content is protected !!